Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. (ROIV) is a healthcare company (biotechnology) based in the United Kingdom. The share price is $38.07, down 1.40% on the day, which values the company at $27.58B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$38.07−1.40% today
Market value
$27.58B
Funk Score
22/100
Against its own history
Well above its usual priceusual price $7.76
200-week average
$16.18135% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Roivant Sciences Ltd. in more detail

ROIV trades at -26.6× next year's expected earnings, 671.4× sales. Measured against its own history, the price is 391% above what its usual multiples would imply ($7.76) — well above its usual price. It sits 135% above its 200-week average of $16.18.

Over the last five fiscal years Roivant Sciences Ltd. has compounded revenue -19.1% a year. Its Funk Score is 22 out of 100 (financial strength 7.0, profitability 0.3, growth 1.3, value 0.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Heavy stock-based pay.

6 of the superinvestors tracked here hold ROIV, including Andrew Spokes (4.1% of the portfolio), David Einhorn (1.9% of the portfolio), Lee Ainslie (0.9% of the portfolio).

Superinvestors holding ROIV

6 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:ROIV vs WST (Roivant Sciences Ltd. vs West Pharmaceutical Services)ROIV vs DGX (Roivant Sciences Ltd. vs Quest Diagnostics)ROIV vs PHG (Roivant Sciences Ltd. vs Koninklijke Philips)ROIV vs DXCM (Roivant Sciences Ltd. vs DexCom)ROIV vs LH (Roivant Sciences Ltd. vs Labcorp Holdings)

All health care companies by market valueLargest companies in the United KingdomAll stocks A–Z

Roivant Sciences Ltd. (ROIV): questions and answers

What is Roivant Sciences Ltd.'s market cap?

Roivant Sciences Ltd. is valued at $27.58B at a share price of $38.07.

Is ROIV overvalued or undervalued?

Against its own history, ROIV is well above its usual price: the price is 391% above the $7.76 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ROIV above its 200-week moving average?

Yes. ROIV is 135.3% above its 200-week average of $16.18. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Roivant Sciences Ltd. growing?

Over the last five fiscal years Roivant Sciences Ltd.'s revenue grew -19.1% a year.

Does ROIV pay a dividend?

Roivant Sciences Ltd. does not currently pay a regular dividend.

Which famous investors own ROIV?

In their latest quarterly filings, Andrew Spokes (4.1% of the portfolio), David Einhorn (1.9% of the portfolio), Lee Ainslie (0.9% of the portfolio), Julian and Felix Baker (0.8% of the portfolio), Andreas Halvorsen (0.6% of the portfolio), Steve Cohen (0.2% of the portfolio) hold ROIV. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Roivant Sciences Ltd. (ROIV) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ROIV

Underlying data: Yahoo Finance; company filings with the SEC.